- Home
- CDE vs QGEN Comparison
CDE vs QGEN Comparison
Compare CDE & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDE | QGEN |
|---|---|---|
| Founded | 1928 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | CDE | QGEN |
|---|---|---|
| Price | $22.90 | $55.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $20.00 | ★ $48.84 |
| AVG Volume (30 Days) | ★ 22.0M | 2.4M |
| Earning Date | 02-18-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 4.33% |
| EPS Growth | N/A | ★ 331.25 |
| EPS | 0.74 | ★ 1.94 |
| Revenue | $1,700,723,000.00 | ★ $2,070,781,000.00 |
| Revenue This Year | $95.35 | $7.12 |
| Revenue Next Year | $35.11 | $5.95 |
| P/E Ratio | $31.04 | ★ $28.76 |
| Revenue Growth | ★ 68.28 | 5.32 |
| 52 Week Low | $4.58 | $39.61 |
| 52 Week High | $23.63 | $57.82 |
Technical Indicators
Market Signals| Indicator | CDE | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 73.13 | 80.30 |
| Support Level | $20.17 | $46.07 |
| Resistance Level | $23.74 | $57.82 |
| Average True Range (ATR) | 1.22 | 1.93 |
| MACD | 0.30 | 0.83 |
| Stochastic Oscillator | 88.09 | 80.50 |
Price Performance
Historical ComparisonAbout CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).